Pena-Cabia, Silvia’s team published research in Biomedicine & Pharmacotherapy in 2021-09-30 | 1492-18-8

Biomedicine & Pharmacotherapy published new progress about Body weight. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Recommanded Product: Calcium folinate.

Pena-Cabia, Silvia; Royuela Vicente, Ana; Ramos Diaz, Ruth; Gutierrez Nicolas, Fernando; Penalver Vera, Angela; Siso Garcia, Isabel; Hitt Sabag, Ricardo; Garcia Lacalle, Concepcion; Pena-Cabia, Ana; Iglesias-Peinado, Irene; Garcia Diaz, Benito; Lopez-Martin, Ana published the artcile< Assessment of exposure-response relationship for bevacizumab in patients with metastatic colorectal cancer>, Recommanded Product: Calcium folinate, the main research area is human bevacizumab metastatic colorectal cancer exposure response relationship; Bevacizumab; Colorectal neoplasms; Drug monitoring; Exposure-response relationship; Treatment outcome.

Limited literature is available for bevacizumab exposure-response relationship and there is not a concentration threshold associated with an optimal disease control. This prospective observational study in patients with metastatic colorectal cancer (mCRC) aims to evaluate, in a real-life setting, the relationship between bevacizumab through concentrations at steady state (Ctrough, SS) and disease control. Ctrough, SS were drawn, coinciding with the radiol. evaluation of the response (progression or clin. benefit). Generalized estimating equations (GEE) anal. was performed. To test the association between Ctrough, SS in each patient with overall survival (OS) or progression-free survival (PFS), Cox proportional hazard models were developed. Data included 50 bevacizumab Ctrough, SS from 27 patients. The GEE model did not suggest any pos. association between bevacizumab Ctrough, SS and clin. benefit (OR 0.99, 95% CI: 0.98-1.02, p = 0.863). The Cox regression showed association between higher median Ctrough, SS with better OS (HR 0.86, 95% CI: 0.73-1.01, p = 0.060), but not with PFS. We cannot confirm a relationship between bevacizumab Ctrough, SS and clin. benefit but this is the first real-world study trying to show a relationship between bevacizumab Ctrough, SS and disease control in mCRC. It was conducted in a small sample size which reduces the level of evidence. Further controlled randomized studies with a sufficient number of patients are required.

Biomedicine & Pharmacotherapy published new progress about Body weight. 1492-18-8 belongs to class alcohols-buliding-blocks, and the molecular formula is C20H21CaN7O7, Recommanded Product: Calcium folinate.

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts